瑞典Affibody   
Affibody是一家瑞典生物技术公司，专注于在其独有的专利技术平台基础上开发新一代生物药品， 这些平台是Affibody®分子和AlbumodTM。

Affibody正在开发一系列创新药物课题，此外也提供半衰期延长技术AlbumodTM，用于对外授权。Affibody与若干公司有持续的商业关系，包括Algeta、Amylin、Swedish Orphan Biovitrum、GE和Thermo Fisher。

Affibody由瑞典皇家理工学院和卡罗琳斯卡研究所的研究人员于1998年创立，总部在瑞典斯德哥尔摩。公司大股东包括HealthCap和Investor Growth Capital。

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.